The use of piperacillin–tazobactam in neonatal and paediatric patients

  title={The use of piperacillin–tazobactam in neonatal and paediatric patients},
  author={Maria F Wolf and Arne Simon},
  journal={Expert Opinion on Drug Metabolism \& Toxicology},
  pages={57 - 69}
  • M. Wolf, A. Simon
  • Published 1 January 2009
  • Medicine
  • Expert Opinion on Drug Metabolism & Toxicology
Background: Piperacillin–tazobactam (PIP/TAZO) has been extensively used in adults with nosocomial infections and with fever and neutropenia. The available data considering the use of PIP/TAZO have not been reviewed in detail. Objective: Review discussing the use of PIP/TAZO in neonatal and paediatric patients. Methods: Medline search focusing on articles published in English. Owing to the paucity of randomized controlled trails, uncontrolled studies and case series were included. Results… 
6 Citations

Emergence of Pseudomonas aeruginosa cross-infection in children with cystic fibrosis attending an Iranian referral pediatric center

In this country CF patients are not segregated from other patients, and transmission of bacteria between these patients and other patients might occur in the wards via personal contact or contaminated environment, and future evaluation for policy of patient segregation is necessary.

Dose-Exposure Simulation for Piperacillin-Tazobactam Dosing Strategies in Infants and Young Children.

To determine appropriate TZP dosing strategies in children 2 months - 6 years according to age and different minimal inhibitory concentrations, post-hoc pharmacokinetic parameter estimates were generated using published clearance and volume of distribution data.

Determination of Free and Total Piperacillin–Tazobactam in Plasma by HPLC–MS–MS: An Adapted Method for Neonates

The validation results of this analytical method made it feasible for being used in a further pilot study of population pharmacokinetics of piperacillin–tazobactam in neonates.



The use of piperacillin/tazobactam (in association with amikacin) in neonatal sepsis: Efficacy and safety data

It is concluded that P/T in association with amikacin is microbiologically and clinically efficacious and safe in the treatment of sepsis in newborns and within 48–72 h of therapy in 93% Gram-negative organisms.

Piperacillin-tazobactam plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients.

This study suggests that piperacillin-tazobactam plus amikacin presents a satisfactory efficacy and a good tolerance as initial empirical therapy for febrile neutropenic children.

Piperacillin/tazobactam in the treatment of Klebsiella pneumoniae infections in neonates.

It is suggested that piperacillin/tazobactam may be a useful antimicrobial agent in neonatal infections caused by beta-lactamase-producing organisms.

Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients.

  • C. ViscoliA. Cometta T. Calandra
  • Medicine, Biology
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
  • 2006
It was concluded that piperacillin-tazobactam could be considered as monotherapy for patients with high-risk febrile neutropenia.

Piperacillin-tazobactam and netilmicin as a safe and efficacious empirical treatment of febrile neutropenic children

This study suggests that piperacillin-tazobactam in association with netilmicin presents a satisfactory efficacy and a good tolerance as empirical therapy for febrile neutropenic children.

Safety Evaluation of Piperacillin/Tazobactam in Very Low Birth Weight Infants

It is demonstrated that piperacillin/tazobactam is a safe and well tolerated drug for preterm infants with bacterial infections, particu-larly those involving the gastrointestinal tract.

Piperacillin-tazobactam in pediatric cancer patients younger than 25 months: a retrospective multicenter survey

Piperacillin-Tazobactam (Pip-TZ) appears to be a safe, and feasible alternative in pediatric cancer patients with febrile neutropenia <25 months of age suggesting that the inclusion of children of all age groups in future prospective controlled studies evaluating Pip-Tazer is justified.

An open, multicenter clinical trial of piperacillin/tazobactam in the treatment of pediatric patients with intra-abdominal infections.

Based on the safety and efficacy results from this study, the advantages of using a single agent for the treatment of mixed infections of the peritoneal cavity and its potential activity against resistant organisms are believed to be significant.

Experience with the use of piperacillin–tazobactam in pediatric non‐renal solid organ transplantation

Pip–Tazo may be a suitable single agent for perioperative prophylaxis in pediatric non‐renal solid organs recipients, however, a prospective comparative study is needed to make final conclusions.

Tolerability of piperacillin/tazobactam in children and adolescents after high dose radio-/chemotherapy and autologous stem cell transplantation

The tolerability of PIP/TAZ appears to be well tolerated in children during the acute phase of HD-SCT, as indicated in 19 children and adolescents who developed a fever during aplasia after high dose radio-/chemotherapy and autologous stem cell transplantation for primary multifocal or relapsed solid tumours.